Ramucirumab As Second-Line Treatment in Patients with Hepatocellular Carcinoma (HCC) and Elevated Alpha-Fetoprotein (AFP) Following Sorafenib: Pooled Results from Two Global Phase 3 Studies (REACH-2 and REACH)
HEPATOLOGY. Bd. 68. 2018 S. 166A-166A
Erscheinungsjahr: 2018
Publikationstyp: Zeitschriftenaufsatz
| Geprüft: | Bibliothek |
Autoren
Llovet, Josep M. (Autor)
Kudo, Masatoshi (Autor)
Finn, Richard (Autor)
Galle, Peter R. (Autor)
Blanc, Jean-Frederic (Autor)
Okusaka, Takuji (Autor)
Chau, Ian (Autor)
Abada, Paolo B. (Autor)
Hsu, Yanzhi (Autor)
Zhu, Andrew X. (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
